Janux Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Janux Therapeutics, Inc. (JANX) reported Increase (Decrease) in Accrued Liabilities of $2.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- Janux Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $4.04M, a 39.82% increase year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$2.03M, a 217.07% decline year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$4.52M.
- Janux Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $6.18M, a 35.12% increase year-over-year.
- Janux Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $6.29M, a 42.11% increase from fiscal 2024.
- Janux Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $4.43M.
- Janux Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$678.00K, a 116.31% decline from fiscal 2022.
- Janux Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $4.16M, a 37.25% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.02M 10-Q · filed 2026-08-06 | -$2.50M derived: sum of 3 quarters · filed 2026-08-06 | $3.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$2.03M 10-Q · filed 2026-05-07 | -$6.55M derived: sum of 2 quarters · filed 2026-05-07 | -$367.00K derived: sum of 3 quarters · filed 2026-05-07 | $2.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.66M derived: sum of 2 quarters · filed 2026-02-26 | $4.56M derived: sum of 3 quarters · filed 2026-08-06 | $6.29M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.07M derived: sum of 2 quarters · filed 2026-08-06 | $10.81M 10-Q · filed 2025-11-06 | $9.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.63M 10-Q · filed 2026-08-06 | $2.99M derived: sum of 3 quarters · filed 2026-08-06 | $7.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.73M 10-Q · filed 2026-05-07 | $100.00K derived: sum of 2 quarters · filed 2026-05-07 | $4.67M derived: sum of 3 quarters · filed 2026-05-07 | $7.73M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.94M derived: sum of 2 quarters · filed 2026-02-26 | $6.00M derived: sum of 3 quarters · filed 2026-02-26 | $4.43M 10-K · filed 2026-02-26 |
| 2024-09-30 | $4.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $7.63M derived: sum of 2 quarters · filed 2025-11-06 | $6.06M 10-Q · filed 2025-11-06 | $6.49M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.49M 10-Q · filed 2025-08-07 | $1.91M derived: sum of 3 quarters · filed 2026-02-26 | -$74.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$1.57M 10-Q · filed 2025-05-08 | -$1.15M derived: sum of 2 quarters · filed 2026-02-26 | -$3.13M derived: sum of 3 quarters · filed 2026-02-26 | -$1.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $426.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.56M derived: sum of 2 quarters · filed 2026-02-26 | -$118.00K derived: sum of 3 quarters · filed 2026-02-26 | -$678.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$544.00K derived: sum of 2 quarters · filed 2024-11-06 | -$1.10M 10-Q · filed 2024-11-06 | -$99.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $883.00K 10-Q · filed 2024-08-07 | $1.89M derived: sum of 3 quarters · filed 2025-02-27 | $4.78M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$560.00K 10-Q · filed 2024-05-08 | $445.00K derived: sum of 2 quarters · filed 2025-02-27 | $3.33M derived: sum of 3 quarters · filed 2025-02-27 | $2.44M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.89M derived: sum of 2 quarters · filed 2025-02-27 | $3.00M derived: sum of 3 quarters · filed 2025-02-27 | $4.16M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.99M derived: sum of 2 quarters · filed 2023-11-07 | $3.15M 10-Q · filed 2023-11-07 | $5.07M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$894.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $264.00K 10-Q · filed 2023-08-08 | $2.19M derived: sum of 3 quarters · filed 2023-08-08 | $2.59M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.16M 10-Q · filed 2023-05-09 | $3.08M derived: sum of 2 quarters · filed 2023-05-09 | $3.49M derived: sum of 3 quarters · filed 2023-05-09 | $4.43M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $2.33M derived: sum of 2 quarters · filed 2023-03-10 | $3.27M derived: sum of 3 quarters · filed 2023-03-10 | $3.03M 10-K · filed 2023-03-10 |
| 2021-09-30 | $409.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.35M derived: sum of 2 quarters · filed 2022-11-10 | $1.11M 10-Q · filed 2022-11-10 | $1.53M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $938.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $698.00K 10-Q · filed 2022-08-09 | $1.12M derived: sum of 3 quarters · filed 2022-08-09 | $1.22M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$240.00K 10-Q · filed 2022-05-10 | $184.00K derived: sum of 2 quarters · filed 2022-05-10 | $283.00K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $424.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $523.00K derived: sum of 2 quarters · filed 2022-03-18 | $624.00K 10-K · filed 2022-03-18 | |
| 2020-09-30 | $99.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $200.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $101.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |